What Metabolomic Diagnostics does

Metabolomic Diagnostics Ltd. is an Ireland-based deep-tech diagnostics company founded in 2013 that develops metabolomics-based biomarker diagnostic solutions for complex diseases, with an initial focus on maternal-fetal health. The company's core technology combines LC-MS/MS mass spectrometry with proprietary informatics, statistics, and machine learning algorithms through its M-SCOUT translational research platform, which evaluates candidate metabolite biomarkers and translates validated panels into clinical IVD assays. Its flagship product, PrePsia, is a blood-based screening test administered as early as week 12 of pregnancy that uses a panel of metabolite biomarkers combined with clinical markers (PlGF, MAP, UTA-PI) and patient characteristics (BMI, race) to generate a personalized risk score for preterm preeclampsia; published clinical research reports a 15% increase in detection rates versus established clinical markers alone.

The company historically generated revenue (if any) through technology licensing and pre-commercial research collaborations, with first commercial product revenues expected in 2025 following its September 2024 acquisition by Trinity Biotech plc for approximately $1.3 million enterprise value. Under Trinity Biotech, PrePsia is commercialized via Trinity's New York State Department of Health-certified Immco diagnostic reference laboratory, with international expansion being examined. Go-to-market combines enterprise field sales through clinical reference laboratories with channel partnerships (Renegade.bio for US co-development, King's College Hospital London for clinical validation) and direct physician engagement with prenatal care providers. The company holds ISO 13485:2016 and ISO 9001:2015 certifications and is pursuing FDA 21 CFR 820 and EU IVDR compliance for its IVD assays. Cumulative disclosed funding exceeded €7 million across multiple rounds (2013-2020) from investors including SOSV, AIB Seed Capital Fund, Enterprise Ireland, and the EU Horizon 2020 SME Instrument.

Name

Metabolomic Diagnostics

Legal name

Metabolomic Diagnostics Ltd.

Website

https://metabolomicdiagnostics.com

Company type

Private

Founded year

2013

Operating status

Acquired

Headcount range

11–50 employees

Short description

Metabolomic Diagnostics is an Ireland-based deep-tech company that develops metabolomics-based blood diagnostic tests for pregnancy complications, with PrePsia as its flagship preterm preeclampsia screening product combining LC-MS/MS mass spectrometry with machine learning risk scoring for prenatal healthcare providers.

Ownership category

akta.pro rank

Product category

Prenatal Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays (HLAAALAN)

akta.pro secondary industries

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Metabolomics & Lipidomics Services (HLAGANAG), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Preeclampsia screening
• Metabolomics diagnostics
• Biomarker discovery
• Mass spectrometry diagnostics
• Maternal health testing

Headquarters

HQ city

Cork

HQ country

Ireland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Test Sales: Sale of PrePsia preeclampsia screening test reagents manufactured in-house and processed through Trinity Biotech's Immco reference laboratory. First revenues expected in 2025.
2. Laboratory Testing Services: Clinical laboratory testing services through certified reference laboratories (Immco) for processing patient samples using the PrePsia test platform.
3. Technology Licensing: Licensing of proprietary biomarker panels, M-SCOUT platform technology, and diagnostic algorithms to partners for development of diagnostic tests in maternal health sector.

Go-to-market motion3 records

Distribution channels3 records

Marketing channels5 records

Core offering

Metabolomic Diagnostics develops and commercialises biomarker-based diagnostic solutions for complex diseases, with its lead product being PrePsia, an early-pregnancy blood test that uses LC-MS/MS mass spectrometry and a proprietary machine-learning algorithm to deliver a personalised risk score for preterm preeclampsia. The company also operates the M-SCOUT translational research platform to discover and validate metabolite biomarker panels and translate them into clinical assays for reference-laboratory use.

Product overview

Metabolomic Diagnostics is a deep-tech company that has developed a diagnostic pipeline combining mass spectrometry with proprietary informatics and statistics solutions. The company's flagship product is PrePsia, a blood test for early pregnancy preeclampsia risk screening, supported by the M-SCOUT translational research platform for biomarker discovery and assay development. The company is also developing solutions for gestational diabetes and preterm birth.

Differentiator

Problem solved

Functional benefit

Brands

• PrePsia: A simple blood test for early pregnancy preeclampsia risk screening using metabolite biomarkers and mass spectrometry technology
• M-SCOUT

Products and services

• PrePsia A simple blood test taken in early pregnancy (around week 12) that uses mass spectrometry to measure metabolite biomarkers combined with clinical markers (PlGF, MAP, UTA-PI) and machine-learning algorithms to generate a personalised preeclampsia risk score; designed for obstetricians, maternal-fetal medicine specialists, and prenatal clinics.
• M-SCOUT Proprietary LC-MS/MS-based translational research platform that integrates a biomarker pipeline for evaluating large lists of candidate metabolite biomarkers in large sample sets, combining analytical workflows with a growing biomarker assay library and bio-statistical tools for IVD prototyping.

Quantifiable outcome

• 15% increase in detection rates for preterm preeclampsia when metabolites combined with blood pressure measurements and Placental Growth Factor (PlGF)
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Five partnerships are on record, tiered minor and core.

• SQU4RE.comminorStrategic or Co-development Partner · 1 November 2023Partnership recognized with Pharma Industry Awards 2023 Partnership Alliance of the Year. Collaboration on statistical analysis and data visualization for biomarker analysis.
• King's College Hospital LondoncoreStrategic or Co-development Partner · 21 September 2023Clinical collaboration with Professor Kypros Nicolaides for research validation of PrePsia test. Principal investigator renowned obstetrician and founder of Fetal Medicine Foundation, UK.
• Preeclampsia FoundationminorGTM or Marketing Partner · 1 May 2022Corporate partnership focused on training healthcare providers, educating patients, and conducting research to improve preeclampsia prediction and maternal health outcomes.
• Renegade.biocoreStrategic or Co-development Partner · 15 February 2022Partnership to jointly develop and launch preeclampsia risk screening test specifically for the US population. Renegade.bio provides clinical laboratory expertise and mission-aligned focus on equitable access to care for underserved communities.
• Codex4SMEs (Interreg)minorStrategic or Co-development Partner · 18 September 2019EU Interreg North-West Europe project focused on companion diagnostics development for SMEs; Diarmuid Cahalane spoke at conference on Route To Market for IVD Companies.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Natera: Natera is a leading provider of prenatal screening tests (Panorama NIPT, Vistara) and reproductive health diagnostics. It is the closest direct competitor in the prenatal risk-screening space with established OB/GYN commercial infrastructure and payor relationships that PrePsia must compete against.
• Sequenom (Laboratory Corporation of America): Sequenom's MaterniT21 NIPT (now part of LabCorp) pioneered non-invasive prenatal screening and remains a market-leading competitor in the prenatal diagnostics space where PrePsia aims to compete.
• Metabolon: Metabolon is a leading metabolomics services and biomarker discovery company using mass spectrometry-based platforms similar to M-SCOUT. It represents a comparable technology platform approach in the metabolomics discovery and diagnostics market.

Broad incumbents

• Trinity Biotech: Trinity Biotech is the acquirer of Metabolomic Diagnostics and operates the Immco reference laboratory used to commercialize PrePsia. It is a broader clinical diagnostics company with a portfolio of diabetes, HIV, and clinical chemistry tests, providing the commercialization channel for the PrePsia product.
• Roche Diagnostics: Roche Diagnostics is a global IVD and prenatal screening incumbent offering broad maternal-fetal medicine test menus. As a large strategic player, it represents both potential competitive pressure and a possible longer-term acquirer for metabolomics-based screening technology.
• Thermo Fisher Scientific: Thermo Fisher manufactures LC-MS/MS instruments and reagents used in metabolomics workflows and offers clinical diagnostic services. It is both a potential technology partner (supplying the underlying MS instrumentation) and a broad competitor in clinical diagnostics.
• Eurofins Scientific: Eurofins operates a global network of clinical diagnostics laboratories including prenatal screening services. It is a broad incumbent in clinical laboratory services and could be a comparable reference lab partner or competitor in European markets.

Regional players

• Yourgene Health: Yourgene Health (now part of Novogene) provides NIPT and reproductive health screening primarily in Europe and Asia-Pacific. It is a comparable prenatal screening peer with overlapping target market and clinical use cases.

Emerging players

• Bio-Techne: Bio-Techne provides proteomics and biomarker research tools including assay kits and analytical reagents used in biomarker discovery. It represents an adjacent enabling technology provider with comparable scientific customer base and biomarker development expertise.
• SomaLogic: SomaLogic operates a proteomics-based biomarker discovery platform (SomaScan) that, like M-SCOUT, aims to identify biomarker panels for clinical diagnostics. It is an emerging multi-omics platform peer focused on translating biomarker discoveries into clinical applications.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/3288046
• Xx.com/MetDX

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds12 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metabolomic Diagnostics